VBIV - VBI Vaccines Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.92
+0.07 (+3.78%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.85
Open1.84
Bid1.75 x 1800
Ask2.10 x 2900
Day's Range1.83 - 1.92
52 Week Range1.68 - 5.10
Volume99,842
Avg. Volume264,291
Market Cap123.616M
Beta0.86
PE Ratio (TTM)N/A
EPS (TTM)-0.89
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.25
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    VBI Vaccines Responds to Unfounded Allegations in Globes Article

    VBI Vaccines Inc. (VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12, 2018, written by Gali Weinreb (the “Article”) alleging that VBI failed to meet its responsibilities of disclosure regarding a court case in Israel.  Those allegations are not only false, but a gross mischaracterization of the facts. VBI holds itself to the highest standards of integrity and has been fully-compliant with disclosure requirements and regulations.

  • GlobeNewswirelast month

    VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business Development

    VBI Vaccines Inc. (VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced the appointment of Christopher McNulty as Chief Financial Officer and Head of Business Development, effective immediately.  Mr. McNulty is an accomplished financial executive in the biopharmaceutical and medical device field, with a strong background in licensing transactions, capital markets and financing strategy, and public company corporate finance. “We are delighted to have Chris join VBI during this very exciting time in the company’s growth trajectory,” said Jeff Baxter, VBI’s President and CEO.

  • GlobeNewswire2 months ago

    VBI Vaccines to Present at the Canaccord Genuity 38th Annual Growth Conference

    VBI Vaccines Inc. (VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston, MA, on Wednesday, August 8, 2018, at 9:30 a.m. EDT. A live webcast of the presentation and a subsequent replay may be accessed by visiting the Investors page of VBI’s website at: www.vbivaccines.com/investors/events-presentations/. A replay of the webcast will be archived on the company’s website for 90 days following the presentation.

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, State Street, Alphabet, and VBI Vaccines — Future Expectations, Projections Moving into 2018

    NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus ...

  • GlobeNewswire2 months ago

    VBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    --Pivotal Phase 3 program for Sci-B-Vac ® Hepatitis B vaccine continues to advance towards topline data expected mid-year 2019--. --Positive safety and immunogenicity data from Phase 1 study of VBI-1501 ...

  • GlobeNewswire2 months ago

    VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit

    CAMBRIDGE, Mass., July 09, 2018-- VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company ...

  • ACCESSWIRE4 months ago

    Wired News – VBI Vaccines Reports Positive Data from Final Phase-1 Study for Preventative CMV Vaccine

    LONDON, UK / ACCESSWIRE / May 14, 2018 / If you want access to our free research report on VBI Vaccines Inc. (NASDAQ: VBIV), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VBIV as the Company's latest news hit the wire. On May 10, 2018, the commercial-stage biopharmaceutical Company, which develops next generation vaccines to address unmet needs in infectious disease and immuno-oncology, reported positive results from the randomized, placebo-controlled Phase-1 study of VBI-1501. Active-Investors.com is currently working on the research report for Adaptimmune Therapeutics PLC (NASDAQ: ADAP), which also belongs to the Healthcare sector as the Company VBI Vaccines.

  • ACCESSWIRE5 months ago

    Blog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine

    Stock Monitor: KemPharm Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on VBI Vaccines Inc. (NASDAQ: VBIV ). If you want ...

  • Benzinga6 months ago

    ICYMI: Penny Stocks, Energy ETF, AR And VR Devices

    In case you missed it, here are some of Benzinga's top stories from Thursday, March 15th, 2018. Energy Stocks And ETFs Struggle For energy investors, the weakness in energy stocks and ETFs that characterized ...

  • Capital Cube9 months ago

    ETFs with exposure to VBI Vaccines, Inc. : December 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VBI Vaccines, Inc. Here are 5 ETFs with the largest exposure to VBIV-US. Comparing the performance and risk of VBI Vaccines, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • VBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
    Capital Cube9 months ago

    VBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017

    Categories: Yahoo FinanceGet free summary analysis VBI Vaccines, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of VBI Vaccines, Inc. – Pieris Pharmaceuticals, Inc. and PDL BioPharma, Inc. (PIRS-US and PDLI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.19 ... Read more (Read more...)

  • Benzinga10 months ago

    VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO

    VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV ) will release results on three clinical trials in the first half of 2018, presenting certain investment opportunities of an uncertain nature. Some on ...